Lexaria Bioscience Corp. (LEXX) has released an update.
Lexaria Bioscience Corp. has reported promising results from an animal study where their DehydraTECH-CBD formulation led to a 7% weight loss and a significant reduction in blood glucose levels. Following these findings, the company is embarking on a comprehensive 8-week animal study to further explore the weight loss and diabetes control potential of their technology. These studies are part of Lexaria’s efforts to enhance the effectiveness of drugs like semaglutide, already used in treatments for diabetes and weight loss, and to potentially offer improved oral dosing options.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
